SCHEMBL2816627

SCHEMBL2816627

CNc1nnc(-c2ccccc2-c2nc3ncccn3c2Nc2c(C)noc2C)o1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 17/20 0.48
MAPT P10636 9/20 0.48
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
BRD4 O60885 1/20 0.43
PKM P14618 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 4/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.38
PTBP1 P26599 1/20 0.38
ALOX15 P16050 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809753 0.84 GAA (0.50) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL2812288 0.81 GAA (0.45) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL15911454 0.76 GAA (0.55) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL15911712 0.76 GAA (0.52) GAAMAPTMAPK1TDP1PKM
SCHEMBL15911486 0.76 GAA (0.52) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL2808308 0.75 GAA (0.48) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL2812308 0.74 GAA (0.47) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL15911618 0.73 GAA (0.53) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL15911664 0.73 GAA (0.49) GAAMAPTMAPK1NPSR1TDP1
SCHEMBL15911422 0.71 GAA (0.47) GAAMAPTMAPK1TDP1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2195322-B1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2014-08-06 EP claimed
US-8278312-B2 Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-10-02 US claimed
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES Merck Patent Gesellschaft Beschrankter Haftung (DE) 2010-09-30 US claimed
EP-2195322-B1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2014-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES TYMS, CCNT1, INSR GAA 1202/4885MAPT 3889/4885MAPK1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.